Jim Cramer Makes Big Claim About Beckton Dickinson (BDX)

We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. Becton, Dickinson and Company (NYSE:BDX) is one of the stocks discussed by Jim Cramer.

Becton, Dickinson and Company (NYSE:BDX) is one of the largest medical devices and laboratory equipment providers in America. Its shares are up by 6.9% over the past year and are down by 3.8% year-to-date. Piper Sandler discussed Becton, Dickinson and Company (NYSE:BDX)’s shares on April 17th as it reduced the share price target to $159 from $170 and kept a Neutral rating on the stock as it adjusted its estimates to account for the firm’s latest guidance. On the 14th, RBC Capital had reduced the share price target to $175 from $195 and maintained a Sector Perform rating. The bank remarked that Becton, Dickinson and Company (NYSE:BDX) was not at the risk of demand disruption, as evidenced by intra-quarter checks. Cramer has discussed healthcare stocks quite a bit recently, and in this appearance, he insisted sticking with Becton, Dickinson and Company (NYSE:BDX) despite the lackluster share price performance:

“I had Tom Polen, the CEO of Beckton Dickinson. And that stock is at an historical low. A low, healthcare, you can’t give these stocks away.”

Why Serve Robotics (SERV) Is Emerging as a Physical AI Growth Story

Source: Unsplash

While we acknowledge the risk and potential of BDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.